Immunosuppression and infectious complications: A hemorrhagic dilemma

Isabelle Malhamé, Amanda Farag, Zhao Gao, Alan Barkun

ABSTRACT

Introduction: Patients treated with immunosuppressive agents for autoimmune diseases are a unique patient population. Simultaneous management of an underlying autoimmune disease and of an opportunistic infection can present a therapeutic dilemma.

Case Report: A 68-year-old female presented with signs and symptoms of vasculitis involving the gastrointestinal tract. After initiation of immunosuppressive treatment, she developed an infectious complication that led to intractable gastrointestinal bleeding.

Conclusion: Current recommendations addressing the management of cytomegalovirus infection in the context of a severe vasculitis are lacking, and our approach to this case may benefit physicians dealing with this clinical dilemma in the future.
Immunosuppression and infectious complications: A hemorrhagic dilemma

Isabelle Malhamé, Amanda Farag, Zhao Gao, Alan Barkun

ABSTRACT

Introduction: Patients treated with immunosuppressive agents for autoimmune diseases are a unique patient population. Simultaneous management of an underlying autoimmune disease and of an opportunistic infection can present a therapeutic dilemma. Case Report: A 68-year-old female presented with signs and symptoms of vasculitis involving the gastrointestinal tract. After initiation of immunosuppressive treatment, she developed an infectious complication that led to intractable gastrointestinal bleeding. Conclusion: Current recommendations addressing the management of cytomegalovirus infection in the context of a severe vasculitis are lacking, and our approach to this case may benefit physicians dealing with this clinical dilemma in the future.

Keywords: Cytomegalovirus, Immunosuppression, Vasculitis

INTRODUCTION

Patients treated with immunosuppressive agents for autoimmune diseases affecting the gastrointestinal tract present a unique and complex challenge. When the symptoms of an opportunistic infection are similar to the underlying autoimmune disease, clinical management becomes even more difficult. We believe that our approach to this case may benefit physicians caring for such patients.

CASE REPORT

A 68-year-old female presented to the emergency department of a peripheral hospital for fatigue and palpable purpurae. Her past medical history included mild hypertension, hypothyroidism, and diabetes, for which she was taking calcium channel blockers, thyroxine, and an oral anti-hyperglycemic. One week after her initial visit, she developed polyarthitis, melena and bright red blood per rectum. Despite initiation of 60 mg of oral prednisone, her symptoms did not improve and she went on to develop hypoxic respiratory failure. In view of her clinical deterioration, she was transferred to a tertiary care hospital. Upon admission, she had both...
upper and lower gastrointestinal bleeding symptoms requiring volume resuscitation as well as transfusions.

Given the constellation of polyarthritis, palpable purpurae, melena, and possible alveolar hemorrhage, we strongly suspected a vasculitic process with gastrointestinal involvement such as an eosinophilic granulomatosis with polyangiitis (EiGPA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), polyarteritis nodosa (PAN), and rheumatoid arthritis associated vasculitis (RAAV) [1]. Pertinent laboratory examinations revealed normal platelet count, INR, eosinophil count, immunoglobulin profile, C3-4 levels, as well as negative C-anca, P-anca, anti-GBM, cryoglobulin, lupus anticoagulants, and rheumatoid factor. She also had negative HIV, hepatitis C and B screens. The patient’s bleeding originated from the distal ileum on capsule endoscopy, CT-scan with contrast, and colonoscopy. She also had diffuse mucosal ulcerations throughout the digestive tract (Figure 1). Given the strong suspicion of underlying vasculitis, the treating team initiated a three days course of 1 g of intravenous methylprednisolone daily. Despite the steroid treatment, and two attempts at arterial embolization, the patient continued to pass large amounts of bloody stools. On day-7 of her admission, given the growing risk of bowel ischemia and perforation associated with subsequent arterial embolization, the patient underwent urgent surgical exploration with resection of the involved bowel. Intra-operative endoscopy visualized the entire small bowel lumen with active arterial bleeding and ulcerations in the proximal and terminal ileum. She had a right hemi-colectomy and loop ileostomy with extended resection of the terminal ileum. The biopsy, which resulted on the second week of hospitalization, suggested a polyarteritis nodosa (PAN) involving the ileum and colon with superimposed cytomegalovirus infection (Figure 2).

The patient was treated with ganciclovir for her infection and rituximab for PAN as a less aggressive treatment alternative to cyclophosphamide. The bleeding persisted from the ileostomy despite a decreasing cytomegalovirus viremia. Given the active PAN, which was thought to be responsible for the ongoing hemorrhage, a course of cyclophosphamide was initiated. The patient remained in the ICU for one month, during which she developed hospital-acquired infections including repeated bacteremias with Staphylococcus aureus, and Candida dubliniensis.

After a brief resolution of the intestinal hemorrhage, the patient had a recurrence of profuse bleeding through the ileostomy. While a repeat gastroscopy and ileoscopy demonstrated deep ulcerations compatible with ischemia of both duodenum and ileum, an explorative laparotomy did not demonstrate transmural necrosis; resection was therefore not carried out. In view of her overall deteriorating condition despite ongoing therapy, it was decided with the patient’s family to pursue a palliative approach and the patient died on day-70 day of admission.

DISCUSSION

Polyarteritis nodosa is a necrotizing, focal segmental vasculitis of medium-sized arteries [1]. The outcome of patients treated for PAN has greatly improved in the last two decades [2]. In this cohort, 37.9% of patients diagnosed with PAN had gastrointestinal involvement, and gastrointestinal manifestations requiring surgery at diagnosis were independent predictors of mortality [2].

Traditionally, hepatitis B has been identified as a possible viral trigger, but infections with cytomegalovirus have also been reported [3–5]. In a multi-centric retrospective survey on cytomegalovirus infection among patients hospitalized with autoimmune diseases in Japan, oral prednisone, pulsed methylprednisolone, and cyclophosphamide were most associated with reactivation [6]. Reactivation of cytomegalovirus, whether previously documented or not, should therefore be considered to be a serious potential complication of the mainstay treatment of vasculitis. In the case of our patient, it is reasonable to believe that initial treatment of her vasculitis with prednisone and methylprednisolone precipitated the cytomegalovirus reactivation.

Expert opinion on vasculitides in the context of viral infections suggests prompt intravenous antiviral treatment and discourages the use of corticosteroid and/or immune-suppressants for patients who are already immunosuppressed [3]. However, the combination of corticosteroids with cyclophosphamide remains the cornerstone of treatment, and herein lays the dilemma [7]. If we were to solely treat the cytomegalovirus we might be undertreating the vasculitis, which could worsen the
CONCLUSION

In conclusion, the patient discussed highlights a unique diagnostic and therapeutic dilemma. The coexistence of active cytomegalovirus infection and severe polyarteritis nodosa resulted in having to choose between possible conflicting therapeutic aims. Clinicians should consider altering standard aggressive combination therapy for the vasculitis while administering antiviral treatment in such patients.

********

Author Contributions

Isabelle Malhamé – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Amanda Farag – Substantial contribution to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Zhao Gao – Substantial contribution to acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Alan Barkun – Substantial contribution to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Edorium Journals: An introduction

About Edorium Journals
Edorium Journals is a publisher of international, high-quality, open access, scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Why should you publish with Edorium Journals?
In less than 10 words: “We give you what no one does”.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial review
All manuscripts submitted to Edorium Journals undergo pre-processing review followed by multiple rounds of stringent editorial reviews.

Peer review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early view version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates about status of your manuscripts.

Our Commitment

Six weeks
We give you our commitment that you will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Four weeks
We give you our commitment that after we receive your page proofs, your manuscript will be published in the journal within 14 days (2 weeks). If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Favored author program
One email is all it takes to become our favored author. You will not only get 15% off on all manuscript but also get information and insights about scholarly publishing.

Institutional membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in publication fees.

Our presence
We have high quality, attractive and easy to read publication format. Our websites are very user friendly and enable you to use the services easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services. Please visit: www.edoriumjournals.com

We welcome you to interact with us, share with us, join us and of course publish with us.